A Phase 2, Proof of Concept Trial Investigating the Safety and Efficacy of the Neoadjuvant Triplet Olaparib, Durvalumab and Bevacizumab in Advanced FIGO Stage IV High Grade Serous Ovarian Cancer
Latest Information Update: 25 Oct 2024
At a glance
- Drugs Bevacizumab (Primary) ; Durvalumab (Primary) ; Olaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms NEOCATS
- 25 Oct 2024 New trial record